Literature DB >> 25278743

An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis.

Patricia S Steeg1, Robin L Anderson2, Menashe Bar-Eli3, Ann F Chambers4, Suzanne A Eccles5, Kent Hunter6, Kazuyuki Itoh7, Yibin Kang8, Lynn M Matrisian9, Jonathan P Sleeman10, Dan Theodorescu11, Erik W Thompson12, Danny R Welch13.   

Abstract

Entities:  

Year:  2009        PMID： 25278743      PMCID： PMC4179907          DOI： 10.1158/1078-0432.CCR-09-1363

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  13 in total

1.  Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells.

Authors:  Yuki Kishida; Hideki Yoshikawa; Akira Myoui
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

2.  The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.

Authors:  John T Price; Julian M W Quinn; Natalie A Sims; Jessica Vieusseux; Kelly Waldeck; Susan E Docherty; Damian Myers; Akira Nakamura; Mark C Waltham; Matthew T Gillespie; Erik W Thompson
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

3.  Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.

Authors:  Georg Feldmann; Surajit Dhara; Volker Fendrich; Djahida Bedja; Robert Beaty; Michael Mullendore; Collins Karikari; Hector Alvarez; Christine Iacobuzio-Donahue; Antonio Jimeno; Kathleen L Gabrielson; William Matsui; Anirban Maitra
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

4.  Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.

Authors:  Brian Titus; Henry F Frierson; Mark Conaway; Keith Ching; Theresa Guise; John Chirgwin; Garret Hampton; Dan Theodorescu
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

5.  Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.

Authors:  Andrea Manni; Sharlene Washington; Laura Craig; Michael Cloud; James W Griffith; Michael F Verderame; Lindsay J Texter; David Mauger; Laurence M Demers; John F Harms; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

7.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

Authors:  Alberta Bergamo; Alessia Masi; Paul J Dyson; Gianni Sava
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

9.  Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.

Authors:  Timothy P Padera; Angera H Kuo; Tohru Hoshida; Shan Liao; Jennifer Lobo; Kevin R Kozak; Dai Fukumura; Rakesh K Jain
Journal:  Mol Cancer Ther       Date:  2008-08-06       Impact factor: 6.261

10.  Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.

Authors:  Gabriela Magenta; Ximena Borenstein; Romina Rolando; María Adela Jasnis
Journal:  BMC Cancer       Date:  2008-02-08       Impact factor: 4.430
View more
  19 in total

1.  Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Authors:  Ernest S Han; Robert A Burger; Kathleen M Darcy; Michael W Sill; Leslie M Randall; Dana Chase; Basmina Parmakhtiar; Bradley J Monk; Benjamin E Greer; Patrick Connelly; Koen Degeest; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2010-09-25       Impact factor: 5.482

Review 2.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

Review 3.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

4.  Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.

Authors:  Terence C Tang; Shan Man; Christina R Lee; Ping Xu; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

Review 5.  Metastasis suppressor genes at the interface between the environment and tumor cell growth.

Authors:  Douglas R Hurst; Danny R Welch
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

Review 6.  Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Authors:  Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

7.  High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.

Authors:  Huaiyu Ma; Xiaoming Li; Zhijian Yang; Satoshi Okuno; Takayuki Kawaguchi; Shigeo Yagi; Michael Bouvet; Robert M Hoffman
Journal:  J Surg Res       Date:  2010-06-25       Impact factor: 2.192

Review 8.  Cancer metastasis as a therapeutic target.

Authors:  Jonathan Sleeman; Patricia S Steeg
Journal:  Eur J Cancer       Date:  2010-03-20       Impact factor: 9.162

9.  A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

Authors:  Eric Guerin; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

10.  Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy.

Authors:  Amanda Tracz; Michalis Mastri; Christina R Lee; Roberto Pili; John M L Ebos
Journal:  J Vis Exp       Date:  2014-04-29       Impact factor: 1.355
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.